Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

~ Experts Spotlight TAAP™ and MPAR® as Next-Generation Solutions for Severe Pain ~

SAN DIEGO, CA / ACCESS Newswire / September 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) (“Ensysce” or the “Company”), a clinical-stage company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today shared key takeaways from its standing-room-only symposium with about 400 attendees, “Pain Management, RE-Invented: A New Era for Analgesia”, held September 3, 2025, at PAINWeek in Las Vegas-the world’s largest pain management conference.

Moderated by Dr. Lynn Kirkpatrick, CEO of Ensysce, the event brought together three leading authorities in pain medicine:

• Dr. Jessica McCoun, Principal Investigator at CenExel Atlanta, opened with strategies for controlling acute post-operative pain using multi-modal therapy to prevent chronification, the gradual transition from acute pain to chronic pain. She stressed the urgent need for powerful yet safer opioid options to restore patient function rapidly while reducing risk.

• Dr. Jeff Gudin, University of Miami Pain Center, examined the latest entrants to the analgesic toolbox-including NAV 1.8 inhibitors-and compared them to Ensysce’s Trypsin Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) technologies, which uniquely use the body’s own chemistry to “switch on” pain relief with proper dosing and “switch off” opioid release in an overdose.

• Dr. William Schmidt, Ensysce’s Chief Medical Officer, presented compelling data differentiating PF614 from other severe pain treatments, outlining the upcoming Phase 3 trial in acute post-surgical pain. He highlighted how TAAP™ and MPAR® could deliver superior analgesia while offering real-world overdose protection.

“This symposium marked our fourth major platform to showcase how Ensysce is reimagining opioid therapy,” said Dr. Kirkpatrick. “PAINWeek brings together the most influential voices in pain medicine, and the response to our clinical vision was overwhelmingly positive, with feedback that our message describing the uniqueness of our technology to improve opioids was clear and compelling. We’re committed to delivering the first opioid that not only treats severe pain effectively but also protects patients from the dangers of abuse and overdose.”

About Ensysce Biosciences

Ensysce Biosciences is a clinical-stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize the risk of both drug abuse and overdose. Ensysce’s products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. For more information, please visit www.ensysce.com.

Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as “may,” “intends,” “can,” “might,” “will,” “expect,” “plan,” “possible,” “believe” and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce’s management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce’s business is subject to additional risks and uncertainties, including among others, possible NASDAQ delisting, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce’s product candidates; the availability or commercial potential of product candidates; continuation of government funding; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce’s and its partners’ ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce’s most recent quarterly report on Form 10-Q and current reports on Form 8-K, available free of charge at the SEC’s website at www.sec.gov. Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

Ensysce Biosciences Company Contact:

Lynn Kirkpatrick, Ph.D.
Chief Executive Officer
(858) 263-4196

Ensysce Biosciences Investor Relations Contact:

Shannon Devine
MZ North America
Main: 203-741-8811
ENSC@mzgroup.us

SOURCE: Ensysce Biosciences Inc.

View the original press release on ACCESS Newswire